Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2752832 | 0.97 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL10073553 | 0.92 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL7057225 | 0.83 | PTGS1 (0.45) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL14071875 | 0.81 | SLC22A6 (0.32) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28099056 | 0.81 | CA12 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL7053481 | 0.76 | SLC22A6 (0.48) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL6831871 | 0.76 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL266829 | 0.74 | PTGS1 (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL121830 | 0.74 | LMNA (0.50) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL17612290 | 0.74 | PTGS1 (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2944308-A1 | Formulations and methods for treating chronic infection | Kiacta Sàrl (CH) | 2015-11-18 | — | — | EP | claimed |
| EP-1885350-A2 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | Neurochem (International) Limited (CH) | 2008-02-13 | — | — | EP | claimed |
| WO-2007004072-A2 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | WO | claimed |
| US-20060252829-A1 | Formulations and methods for treating amyloidosis | KIACTA SARL (CH) | 2006-11-09 | — | — | US | claimed |
| EP-2944308-A1 | Formulations and methods for treating chronic infection | Kiacta Sàrl (CH) | 2015-11-18 | — | — | EP | disclosed |
| EP-1885350-B9 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA S RL (CH) | 2015-06-17 | — | — | EP | disclosed |
| EP-1885350-B1 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA S RL (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20130296434-A1 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA SARL (CA) | 2013-11-07 | — | — | US | disclosed |
| US-8372886-B2 | Treatment of renal disorders, diabetic nephropathy and dyslipidemias | KIACTA SARL (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20120270939-A1 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA SARL | 2012-10-25 | — | — | US | disclosed |
| US-8178580-B2 | Formulations and methods for treating amyloidosis | KIACTA SARL (CH) | 2012-05-15 | — | — | US | disclosed |
| EP-1968561-B1 | TREATMENT OF DIABETIC NEPHROPATHY | BELLUS HEALTH INT LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20080262088-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR TREATING METABOLIC DISORDERS AND DIABETES | KIACTA SARL (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1968561-A2 | TREATMENT OF RENAL DISORDERS, DIABETIC NEPHROPATHY AND DYSLIPIDEMIAS | Neurochem (International) Limited (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008078176-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR TREATING METABOLIC DISORDERS AND DIABETES | BELLUS HEALTH (INTERNATIONAL) LIMITED (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1885350-A2 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | Neurochem (International) Limited (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007125385-A2 | TREATMENT OF RENAL DISORDERS, DIABETIC NEPHOPATHY AND DYSLIPIDEMIAS | NEUROCHEM (INTERNATIONAL) LIMITED (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070238788-A1 | Treatment of renal disorders, diabetic nephropathy and dyslipidemias | KIACTA SARL (CH) | 2007-10-11 | — | — | US | disclosed |
| WO-2007004072-A2 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | WO | disclosed |
| US-20060252829-A1 | Formulations and methods for treating amyloidosis | KIACTA SARL (CH) | 2006-11-09 | — | — | US | disclosed |